Literature DB >> 3135223

Enhancement of learning and memory in mice by a benzodiazepine antagonist.

H Lal1, B Kumar, M J Forster.   

Abstract

Benzodiazepines, a class of drugs widely employed as anxiolytics and anticonvulsants, can induce impairments of learning and memory. The purpose of the present investigation was to determine if a benzodiazepine receptor antagonist, flumazenil (Ro 15-1788), could enhance learning and memory. Pretraining injection of flumazenil (2.5 to 40.0 mg/kg) was found to enhance both learning and memory in a test requiring young mice to discriminate the correct arm of a T-maze to escape mild electric shock. In a second test, which required mice to passively avoid a dark chamber after shock, flumazenil pretreatment prevented the occurrence of amnesia induced by the cholinergic receptor antagonist scopolamine. It is hypothesized that flumazenil may facilitate learning or memory processes by reversing a negative modulatory influence of endogenous diazepam-like ligands for benzodiazepine receptors.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3135223     DOI: 10.1096/fasebj.2.11.3135223

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  15 in total

1.  Infantile stimulation and the role of the benzodiazepine receptor system in adult acquisition of two-way avoidance behavior.

Authors:  R M Escorihuela; A Fernández-Teruel; F J Núñez; A Zapata; A Tobeña
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

Review 2.  Behavioral screening for cognition enhancers: from indiscriminate to valid testing: Part I.

Authors:  M Sarter; J Hagan; P Dudchenko
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

3.  Bidirectional effects of benzodiazepine binding site ligands on active avoidance acquisition and retention: differential antagonism by flumazenil and beta-CCt.

Authors:  Miroslav M Savić; Dragan I Obradović; Nenad D Ugresić; James M Cook; P V V S Sarma; Dubravko R Bokonjić
Journal:  Psychopharmacology (Berl)       Date:  2005-02-18       Impact factor: 4.530

Review 4.  GABA(A) receptors and their associated proteins: implications in the etiology and treatment of schizophrenia and related disorders.

Authors:  Erik I Charych; Feng Liu; Stephen J Moss; Nicholas J Brandon
Journal:  Neuropharmacology       Date:  2009-07-23       Impact factor: 5.250

5.  Agonizing over antagonizing: what do benzodiazepine receptor antagonists demonstrate?

Authors:  M Sarter; G G Berntson; J P Bruno; B S Givens
Journal:  Psychopharmacology (Berl)       Date:  1996-07       Impact factor: 4.530

Review 6.  Activating the damaged basal forebrain cholinergic system: tonic stimulation versus signal amplification.

Authors:  M Sarter; J P Bruno; P Dudchenko
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

7.  Spontaneous exploration of a 6-arm radial tunnel maze by basal forebrain lesioned rats: effects of the benzodiazepine receptor antagonist beta-carboline ZK 93 426.

Authors:  M Sarter; T Steckler
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

8.  Effects of benzodiazepine receptor ligands on the performance of an operant delayed matching to position task in rats: opposite effects of FG 7142 and lorazepam.

Authors:  B J Cole; M Hillmann
Journal:  Psychopharmacology (Berl)       Date:  1994-07       Impact factor: 4.530

9.  Flumazenil and tacrine increase the effectiveness of ondansetron on scopolamine-induced impairment of spatial learning in rats.

Authors:  M Diez-Ariza; C Redondo; M García-Alloza; B Lasheras; J Del Río; M J Ramírez
Journal:  Psychopharmacology (Berl)       Date:  2003-07-04       Impact factor: 4.530

Review 10.  Benzodiazepines in the brain. Their origin and possible biological roles.

Authors:  J H Medina; C Peña; M Piva; C Wolfman; M L de Stein; C Wasowski; C Da Cunha; I Izquierdo; A C Paladini
Journal:  Mol Neurobiol       Date:  1992       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.